CX Institutional’s Globus Medical GMED Stock Holding History

CX Institutional’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-159	Closed	-$14K	–	1600
2026 Q1	$14K	Buy	+159	New	+$14.3K	﹤0.01%	1210

Other funds holding GMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

CX Institutional's GMED Position: Q2 2026 in Review

CX Institutional sold out of Globus Medical (GMED) in Q2 2026, closing a stake of 159 shares — an estimated $14K sold.

CX Institutional first reported a position in GMED in Q1 2026 and held it in 1 quarter. The position peaked at $14K in Q1 2026. 599 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

CX Institutional reported no remaining Globus Medical position as of Q2 2026 after selling out during the quarter.
CX Institutional sold 159 Globus Medical shares in Q2 2026, an estimated $14K.
CX Institutional first reported a position in Globus Medical in Q1 2026 and held it in 1 quarter.
CX Institutional's Globus Medical position peaked at $14K in Q1 2026.
599 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.